4basebio PLC
4BB
Company Profile
Business description
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Contact
25 Norman Way
Over
CambridgeCB24 5QE
GBRT: +44 1223967943
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
110
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.70 | 41.30 | 0.46% |
| CAC 40 | 8,121.07 | 0.00 | 0.00% |
| DAX 40 | 24,283.97 | 4.43 | -0.02% |
| Dow JONES (US) | 48,392.86 | 257.97 | 0.54% |
| FTSE 100 | 9,865.97 | 31.45 | -0.32% |
| HKSE | 25,801.77 | 111.24 | 0.43% |
| NASDAQ | 23,429.19 | 121.57 | 0.52% |
| Nikkei 225 | 50,402.39 | 895.18 | 1.81% |
| NZX 50 Index | 13,508.30 | 174.90 | 1.31% |
| S&P 500 | 6,876.95 | 42.45 | 0.62% |
| S&P/ASX 200 | 8,699.90 | 39.70 | 0.46% |
| SSE Composite Index | 3,917.36 | 26.92 | 0.69% |